logo
logo

Ray Therapeutics Closes $6M Seed Financing To Advance Novel Optogenetics Platform To Treat Blinding Diseases

Jan 04, 2022•over 3 years ago

Amount Raised

$6 Million

Round Type

seed

San Diego

Description

Ray Therapeutics, a biotech company developing optogenetic gene therapies for patients with blinding diseases, today announced the closing of a $6M seed financing round, led by 4BIO Capital.

Company Information

Company

Ray Therapeutics

Location

San Diego, California, United States

About

Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases. The company is developing its lead candidate Ray-001 in retinitis pigmentosa, a degenerative retinal disease with significant unmet medical need. The company’s mission is to use optogenetics to restore vision, independent of genetic mutation for patients with inherited retinal diseases. Ray Therapeutics is based in San Diego, CA. For additional information, please visit www.raytherapeutics.com.